Yes, marijuana is currently a Schedule I controlled substance under federal law. The Drug Enforcement Administration (DEA) classifies it alongside heroin, LSD, and ecstasy as a drug with “no currently accepted medical use and a high potential for abuse.” That classification has been in place since 1970, but a formal process to move marijuana to Schedule III is underway and could change its legal status significantly.
What Schedule I Actually Means
The federal Controlled Substances Act sorts drugs into five categories, or “schedules,” based on two main factors: how likely a drug is to be abused and whether it has an accepted medical use. Schedule I is the most restrictive tier. To land there, a substance must meet all three criteria: high potential for abuse, no currently accepted medical use in the United States, and a lack of accepted safety standards for use under medical supervision.
Schedule III, by comparison, is for drugs with moderate to low potential for physical dependence and a recognized medical use. Common Schedule III substances include testosterone, ketamine, and certain medications containing small amounts of codeine. The gap between Schedule I and Schedule III is enormous in terms of legal consequences, research access, and how the federal government views a substance’s medical value.
Why Marijuana’s Classification Is Controversial
The core tension is straightforward: the federal government says marijuana has no accepted medical use, while 24 states, Washington D.C., Guam, and the Northern Mariana Islands have legalized it for recreational use. Eight additional states allow limited medical access to low-THC cannabis or CBD oil. More than 30,000 healthcare providers are authorized to recommend marijuana to over six million registered patients across the country.
The Department of Health and Human Services (HHS) conducted a formal scientific review and concluded that marijuana does have accepted medical uses, specifically for pain, anorexia related to medical conditions, and nausea and vomiting such as what occurs during chemotherapy. The review also examined evidence for its use in treating anxiety, epilepsy, inflammatory bowel disease, and PTSD. HHS found that marijuana can produce physical and psychological dependence, but that the physical dependence is moderate to low and that most users do not develop high psychological dependence. Based on those findings, HHS formally recommended that marijuana no longer meets the criteria for Schedule I.
The Push to Reschedule to Schedule III
In May 2024, the DEA proposed a rule to move marijuana from Schedule I to Schedule III, based on the HHS recommendation. The proposal drew massive public attention, generating over 42,000 public comments. The DEA scheduled an administrative hearing for January 21, 2025, but a legal appeal by an involved party caused the hearing to be postponed indefinitely.
The situation grew more complicated in mid-2025. The DEA’s only administrative law judge announced retirement effective August 1, 2025, leaving the agency with no judge to preside over the rescheduling hearing or any of its other pending enforcement cases. Federal law requires that these hearings be conducted by an administrative law judge, so the process cannot move forward until one is appointed. All filings in the case are now being forwarded directly to the DEA Administrator.
In December 2025, President Trump issued an executive order instructing the attorney general to expedite the rescheduling process. But without a judge in place, the timeline remains uncertain.
What Would Change With Schedule III
If marijuana is reclassified to Schedule III, the practical effects would ripple through several areas of daily life, business, and science.
Criminal penalties: Federal trafficking charges for Schedule I substances carry up to 20 years in prison. For Schedule III, the maximum drops to 10 years. If a death or serious injury results from use, Schedule I penalties range from 20 years to life, while Schedule III caps at 15 years. Maximum fines also drop, from $1 million to $500,000 for individuals.
Taxes for cannabis businesses: A provision in the tax code called Section 280E prevents businesses that traffic in Schedule I or II substances from deducting ordinary business expenses on federal taxes. This has been a crushing financial burden on state-legal marijuana companies, which pay taxes on their gross income rather than net profit. Moving marijuana to Schedule III would eliminate this restriction, allowing cannabis businesses to deduct rent, payroll, and other normal operating costs like any other business.
Medical research: Schedule I status creates significant bureaucratic barriers for scientists who want to study marijuana. Researchers need special registrations and approvals that make clinical trials slower and more expensive to launch. Schedule III status would simplify the registration process, potentially opening the door to larger and more rigorous studies on marijuana’s medical benefits and risks.
What Rescheduling Would Not Change
Moving to Schedule III would not make marijuana legal for recreational use under federal law. It would still be a controlled substance, and unauthorized possession or distribution would still be a federal crime, just with lower maximum penalties. State marijuana programs, both medical and recreational, would continue to operate in a legal gray area relative to federal law, though the conflict would be less stark.
Rescheduling also would not automatically make marijuana available by prescription at your local pharmacy. The existing state-level dispensary systems would likely remain the primary way patients access cannabis, at least until the FDA establishes new regulatory frameworks for Schedule III marijuana products. The shift is better understood as a change in how seriously the federal government treats marijuana offenses and how it views the drug’s medical legitimacy, not as full legalization.